• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

PSMA-PET–determined disease extent emerges as potential prognostic marker in high-risk nmCRPC

Article

Pelvic lymph node involvement and polymetastases detected with PSMA-PET imaging were linked to significantly lower overall survival rates in patients initially diagnosed with non-metastatic, castration-resistant prostate based on conventional imaging.

Results from a multicenter retrospective study presented during the 2023 ASCO Annual Meeting showed that that pelvic lymph node involvement and polymetastatic disease detected by PSMA-PET imaging are associated with a significantly worse prognosis in patients who are initially diagnosed with non-metastatic castration-resistant prostate cancer (nmCRPC) based on conventional imaging.1

“PSMA-PET disease extent provides a potential novel additional risk stratification for (patients) with nmCRPC without distant metastasis based on conventional imaging,” wrote Wolfgang Fendler, MD, and colleagues.

“PSMA-PET disease extent provides a potential novel additional risk stratification for (patients) with nmCRPC without distant metastasis based on conventional imaging,” wrote Wolfgang Fendler, MD, and colleagues.

For the retrospective analysis, the researchers reviewed PSMA-PET scans for 200 patients who were initially diagnosed via conventional imaging with nmCRPC. These patients also had an International Society of Urological Pathology (ISUP) grade 4 or higher, and/or a prostate-specific antigen doubling time (PSADT less than or equal to 10 months, according to the study.

The study authors found that polymetastatic disease (five or more polymetastases) on PSMA PET imaging had a 1.93 hazard ratio (HR). While the median overall survival rate and new metastases-free survival rate (nMFS) for the cohort were 74 months and 60 months, respectively, the researchers found that those with polymetastatic disease had a median overall survival rate of 61 months and a 38-month nMFS.

Initial pelvic lymph node involvement had no impact on the nMFS rate, according to the study authors. However, they did note a significant association with a shorter mean overall survival rate (2.01 HR). Patients with initial pelvic lymph node involvement had a median overall survival rate of 55 months in comparison to the aforementioned 74-month overall survival rate in the cohort.

“PSMA-PET disease extent provides a potential novel additional risk stratification for (patients) with nmCRPC without distant metastasis based on conventional imaging,” wrote Wolfgang Fendler, MD, who is affiliated with the Department of Nuclear Medicine at the University of Duisburg-Essen and the German Cancer Consortium (DKTK) at University Hospital Essen in Essen, Germany, and colleagues.

While the researchers noted a 1.58 HR in patients with prior definitive radiotherapy (RT) and a 1.41 HR for those with a Gleason grade greater than or equal to eight, they noted these factors had no significant impact on overall survival rates. The PSA level and PSADT also had no impact on survival rates, according to the study authors.

Reference

1. Hadaschik BA, Eiber M, Weber M, et al. Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study. J Clin Oncol 41, no. 16_suppl. doi: 10.1200/JCO.2023.41.16_suppl.5010

Related Videos
David I. Lee, MD, FACS, answers a question during a video interview
Todd M. Morgan, MD, answers a question during a Zoom video interview
Man talking with doctor | Image Credit: © rocketclips - stock.adobe.com
Prostate cancer cell division | Image Credit: © PRB ARTS - stock.adobe.com
Group of doctors reading a document | Image Credit: © Flamingo Images - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.